Analysis of one-year follow-up results and treatment costs of patients with PTE in a tertiary care center
Yıl: 2023 Cilt: 71 Sayı: 4 Sayfa Aralığı: 390 - 399 Metin Dili: İngilizce DOI: 10.5578/tt.20239607 İndeks Tarihi: 29-12-2023
Analysis of one-year follow-up results and treatment costs of patients with PTE in a tertiary care center
Öz: Introduction: Pulmonary thromboembolism (PTE) is a life-threatening disease, with substantial treatment-related complications, difficult follow-up, treatment compliance, and high costs. This study aimed to assess treatment costs with various maintenance therapy regimens, complications, and patient adherence to treatment over a one-year follow-up period. Materials and Methods: This observational, prospective study included 142 patients with PTE who received maintenance anticoagulation therapy between November 2020 and March 2023. The patients were observed at three-month intervals for a year. Possible treatment-related complications, recurrence, mortality, and treatment costs were recorded. Results: Our results showed that there was no significant difference in bleeding risk based on the drugs used for initial or maintenance treatment. In mainte- nance therapy, low-molecular-weight heparin (LMWH), warfarin, and direct oral anticoagulant (DOAC) treatment regimens had similar treatment adher- ence and comparable efficacy and safety in terms of recurrence and bleeding (p> 0.05). Four patients (2.8%) were diagnosed with chronic thromboem- bolic disease. The one-year mortality rate was 24.6% (n= 35), of which 82.9% (n= 29) occurred within the first three months. Hospital mortality rates with the different maintenance therapies were 8.8% in the LMWH group, 5.7% in the warfarin group, and 3.2% in the DOAC group. The annual cost of using LMWH was higher than that of rivaroxaban, apixaban, and warfarin (p< 0.001) while there was no significant cost difference between DOACs and warfarin (p> 0.05). Conclusion: In our study, the LMWH, warfarin, and DOAC treatment regimens had similar efficacy, safety, and patient compliance. In terms of cost, LMWH was the costliest while DOAC and warfarin were similar.
Anahtar Kelime: Üçüncü basamak bir merkezde PTE’li hastaların bir yıllık takip sonuçları ve tedavi maliyetlerinin analizi
Öz: Giriş: Pulmoner tromboemboli (PTE); tedaviye bağlı ciddi komplikasyonlar gelişebilen, takibi ve tedavi uyumu zor olan, ciddi mali- yete sahip önemli bir morbidite ve mortalite nedenidir. Bu çalışmanın amacı çeşitli tedavi rejimlerinde hastaların tedaviye uyumunun, tedaviye bağlı gelişebilecek komplikasyonların değerlendirilmesi ve tedavi maliyetlerinin belirlenmesidir. Materyal ve Metod: Bu prospektif, gözlemsel çalışmaya Kasım 2020-Mart 2023 tarihleri arasında PTE tanısı alan ve idame antikoagü- lan tedavi planlanan 142 hasta dahil edildi. Hastalar üçer ay aralıklarla bir yıl boyunca takip edildi. Tedaviye bağlı gelişebilecek komplikasyonlar, nüks, mortalite ve tedavi maliyetleri kaydedildi. Bulgular: Araştırma sonuçlarımız başlangıçta ve idame tedavide kullanılan ilaçlar ile kanama güvenilirliği arasında anlamlı fark olma- dığını göstermiştir. İdame tedavide de DMAH, varfarin ve DOAK tedavi rejimlerinin tedavi uyumu, rekürrens ve kanama yönünden benzer etkinlik ve güvenilirliğe sahip olduğunu göstermiştir (nüks için p= 1,000, p= 1,000, p= 1,000 sırası ile, kanama için p= 1,000, p= 1,000, p= 0,577 sırası ile). Dört hastaya (%2,8) kronik tromboembolik hastalık (KTEH) tanısı konmuştur. Bir yıllık mortalite ora- nımız %24,6 (35 hasta) olup, %82,8’i (29 hasta) ilk üç ay içerisindeydi. İdame tedavilerin hastane mortalite oranları; DMAH verilen grupta %8,8, varfarin grubunda %5,7, DOAK grubunda ise %3,2 olarak izlendi. Maliyet değerlendirilmesinde DMAH kullanmanın yıllık maliyetinin rivaroksaban, apiksaban ve varfarin kullanımından daha yüksek olduğunu (p< 0,001), DOAK’lar ile varfarin arasın- da ise anlamlı fark olmadığını göstermiştir (p= 1,000). Sonuç: Çalışmamızda DMAH, varfarin ve DOAK tedavi rejimlerinin etkinlik ve güvenilirlikleri benzer bulunmuştur. Maliyet yönünden DMAH’ler yüksek maliyete sahip olup DOAK ve varfarin maliyetleri ise benzerdir.
Anahtar Kelime: Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
- 1. Tarbox AK, Swaroop M. Pulmonary embolism. Int J Crit Illn Inj Sci 2013; 3(1): 69-72. https://doi. org/10.4103/2229-5151.109427
- 2. Rivera-Lebron B, McDaniel M, Ahrar K, Alrifai A, Dudzinski DM, Fanola C, et al. Diagnosis, treatment and follow up of acute pulmonary embolism: Consensus practice from the PERT Consortium. Clin Appl Thromb Hemost 2019; 25: 1076029619853037. https://doi. org/10.1177/1076029619853037
- 3. Klok FA, Cohn DM, Middeldorp S, Scharloo M, Büller HR, van Kralingen KW, et al. Quality of life after pulmonary embolism: Validation of the PEmb-QoL Questionnaire. J Thromb Haemost 2010; 8(3): 523-32. https://doi. org/10.1111/j.1538-7836.2009.03726.x
- 4. Fanikos J, Rao A, Seger AC, Carter D, Piazza G, Goldhaber SZ. Hospital costs of acute pulmonary embolism. Am J Med 2013; 126(2): 127-32. https://doi.org/10.1016/j. amjmed.2012.07.025
- 5. Spyropoulos AC, Lin J. Direct medical costs of venous thromboembolism and subsequent hospital readmission rates: An administrative claims analysis from 30 managed care organizations. J Manag Care Pharm 2007; 13(6): 475-86. https://doi.org/10.18553/jmcp.2007.13.6.475
- 6. Turk M, Aldag Y, Oguzulgen I, Ekim N. A cost comparison of warfarin vs enoxaparine or new oral anticoagulants used for the treatment of patients with pulmonary embo- lism. Tuberk Toraks 2016; 64(3): 198-205. https://doi. org/10.5578/tt.24153
- 7. Garcia DA, Crowther M, Moreira ME. Management of bleeding in patients receiving direct oral anticoagulants. U: UpToDate, Post TW ur UpToDate [Internet] Waltham, MA: UpToDate. 2018.
- 8. Arseven O, Bingöl Z, Çöplü L, Erol S, Oğuzülgen İ, Okumuş N, et al. Türk Toraks Derneği Pulmoner Tromboembolizm Tanı ve Tedavi Uzlaşı Raporu. 2021.
- 9. Chatterjee S, Chakraborty A, Weinberg I, Kadakia M, Wilensky RL, Sardar P, et al. Thrombolysis for pulmonary embolism and risk of all-cause mortality, major bleeding, and intracranial hemorrhage: A meta-analysis. JAMA 2014; 311(23): 2414-21. https://doi.org/10.1001/ jama.2014.5990
- 10. Marti C, John G, Konstantinides S, Combescure C, Sanchez O, Lankeit M, et al. Systemic thrombolytic ther- apy for acute pulmonary embolism: A systematic review and meta-analysis. Eur Heart J 2015; 36(10): 605-14. https://doi.org/10.1093/eurheartj/ehu218
- 11. Yilmazel Ucar E, Araz O, Kerget B, Yilmaz N, Akgun M, Saglam L. Comparison of long term outcomes of 50 and 100 mg rt PA in the management of acute pulmonary thromboembolism. Clin Respir J 2018; 12(4): 1628-34. https://doi.org/10.1111/crj.12721
- 12. Ucar EY, Akgun M, Araz O, Tas H, Kerget B, Meral M, et al. Comparison of LMWH versus UFH for hemorrhage and hospital mortality in the treatment of acute massive pul- monary thromboembolism after thrombolytic treatment: Randomized controlled parallel group study. Lung 2015; 193(1): 121-7. https://doi.org/10.1007/s00408-014- 9660-z
- 13. Ucar EY, Araz O, Akgun M, Meral M, Kalkan F, Saglam L, et al. Low-molecular-weight heparin use with thromboly- sis: Is it effective and safe? Ten years’ clinical experience. Respiration 2013; 86(4): 318-23. https://doi. org/10.1159/000346203
- 14. Wysokinski WE, Houghton DE, Casanegra AI, Vlazny DT, Bott Kitslaar DM, Froehling DA, et al. Comparison of apix- aban to rivaroxaban and enoxaparin in acute cancer asso- ciated venous thromboembolism. Am J Hematol 2019; 94(11): 1185-92. https://doi.org/10.1002/ajh.25604
- 15. Uppuluri EM, Burke KR, Haaf CM, Shapiro NL. Assessment of venous thromboembolism treatment in patients with cancer on low molecular weight heparin, warfarin, and the direct oral anticoagulants. J Oncol Pharm Pract 2019; 25(2): 261-8. https://doi. org/10.1177/1078155217730129
- 16. Li A, Garcia DA, Lyman GH, Carrier M. Direct oral antico- agulant (DOAC) versus low-molecular-weight heparin (LMWH) for treatment of cancer associated thrombosis (CAT): A systematic review and meta-analysis. Thromb Res 2019; 173: 158-63. https://doi.org/10.1016/j.throm- res.2018.02.144
- 17. Cohen AT, Sah J, Dhamane AD, Hines DM, Lee T, Rosenblatt L, et al. Effectiveness and safety of apixaban vs warfarin in patients with venous thromboembolism with risk factors for bleeding or for recurrences. Adv Ther 2023; 40(12): 5447-63. https://doi.org/10.1007/s12325- 023-02440-1
- 18. Lawal OD, Aronow HD, Shobayo F, Hume AL, Taveira TH, Matson KL, et al. Comparative effectiveness and safety of direct oral anticoagulants and warfarin in patients with atrial fibrillation and chronic liver disease: A nationwide cohort study. Circulation 2023; 147(10): 782-94. https:// doi.org/10.1161/CIRCULATIONAHA.122.060687
- 19. Rungjirajittranon T, Owattanapanich W, Chinthammitr Y, Ruchutrakool T, Suwanawiboon B. Direct oral anticoagu- lants versus low-molecular-weight heparins for the treat- ment of acute venous thromboembolism in patients with gastrointestinal cancer: A systematic review and meta-analysis. Thromb J 2022; 20(1): 41. https://doi. org/10.1186/s12959-022-00399-7
- 20. Song Y, Yang D, Hou D, She J, Song Y. Comparison of the efficacy and safety of rivaroxaban and low-molecu- lar-weight heparin in Chinese lung cancer patients with nonhigh-risk pulmonary embolism. Thromb Journal 2023; 21(1): 1-14. https://doi.org/10.1186/s12959-023- 00453-y
- 21. Cohen A, Keshishian A, Lee T, Wygant G, Rosenblatt L, Hlavacek P, et al. Effectiveness and safety of apixaban, low-molecular-weight heparin, and warfarin among venous thromboembolism patients with active cancer: A US claims data analysis. Thromb Haemost 2021; 121(3): 383-95. https://doi.org/10.1055/s-0040-1718728
- 22. Weycker D, Wygant GD, Guo JD, Lee T, Luo X, Rosenblatt L, et al. Bleeding and recurrent VTE with apixaban vs war- farin as outpatient treatment: Time-course and subgroup analyses. Blood Advances 2020; 4(2): 432-9. https://doi. org/10.1182/bloodadvances.2019001081
- 23. Dentali F, Riva N, Turato S, Grazioli S, Squizzato A, Steidl L, et al. Pulmonary embolism severity index accurately predicts long-term mortality rate in patients hospitalized for acute pulmonary embolism J Thromb Haemost 2013; 11(12): 2103. https://doi.org/10.1111/jth.12420
- 24. Justyna A, Dzikowska-Diduch O, Pacho S, Ciurzynski M, Skowronska M, Wyzgal-Chojecka A, et al. Decreased hae- moglobin level measured at admission predicts long term mortality after the first episode of acute pulmonary embo- lism. J Clin Med 2022; 11(23): 7100. https://doi. org/10.3390/jcm11237100
- 25. Coşkuner MB, Öztuna F, Bülbül Y, Özsu S. The cost of pulmonary thromboembolism treatment. Tuberk Toraks 2020; 68(3): 293-304. https://doi.org/10.5578/tt.70104
| APA | Ergül E, Yilmazel Ucar E, Araz O, Aksakal A, Kerget B, SAGLAM L (2023). Analysis of one-year follow-up results and treatment costs of patients with PTE in a tertiary care center. , 390 - 399. 10.5578/tt.20239607 |
| Chicago | Ergül Ersin,Yilmazel Ucar Elif,Araz Omer,Aksakal Alperen,Kerget Bugra,SAGLAM Leyla Analysis of one-year follow-up results and treatment costs of patients with PTE in a tertiary care center. (2023): 390 - 399. 10.5578/tt.20239607 |
| MLA | Ergül Ersin,Yilmazel Ucar Elif,Araz Omer,Aksakal Alperen,Kerget Bugra,SAGLAM Leyla Analysis of one-year follow-up results and treatment costs of patients with PTE in a tertiary care center. , 2023, ss.390 - 399. 10.5578/tt.20239607 |
| AMA | Ergül E,Yilmazel Ucar E,Araz O,Aksakal A,Kerget B,SAGLAM L Analysis of one-year follow-up results and treatment costs of patients with PTE in a tertiary care center. . 2023; 390 - 399. 10.5578/tt.20239607 |
| Vancouver | Ergül E,Yilmazel Ucar E,Araz O,Aksakal A,Kerget B,SAGLAM L Analysis of one-year follow-up results and treatment costs of patients with PTE in a tertiary care center. . 2023; 390 - 399. 10.5578/tt.20239607 |
| IEEE | Ergül E,Yilmazel Ucar E,Araz O,Aksakal A,Kerget B,SAGLAM L "Analysis of one-year follow-up results and treatment costs of patients with PTE in a tertiary care center." , ss.390 - 399, 2023. 10.5578/tt.20239607 |
| ISNAD | Ergül, Ersin vd. "Analysis of one-year follow-up results and treatment costs of patients with PTE in a tertiary care center". (2023), 390-399. https://doi.org/10.5578/tt.20239607 |
| APA | Ergül E, Yilmazel Ucar E, Araz O, Aksakal A, Kerget B, SAGLAM L (2023). Analysis of one-year follow-up results and treatment costs of patients with PTE in a tertiary care center. Tüberküloz ve Toraks, 71(4), 390 - 399. 10.5578/tt.20239607 |
| Chicago | Ergül Ersin,Yilmazel Ucar Elif,Araz Omer,Aksakal Alperen,Kerget Bugra,SAGLAM Leyla Analysis of one-year follow-up results and treatment costs of patients with PTE in a tertiary care center. Tüberküloz ve Toraks 71, no.4 (2023): 390 - 399. 10.5578/tt.20239607 |
| MLA | Ergül Ersin,Yilmazel Ucar Elif,Araz Omer,Aksakal Alperen,Kerget Bugra,SAGLAM Leyla Analysis of one-year follow-up results and treatment costs of patients with PTE in a tertiary care center. Tüberküloz ve Toraks, vol.71, no.4, 2023, ss.390 - 399. 10.5578/tt.20239607 |
| AMA | Ergül E,Yilmazel Ucar E,Araz O,Aksakal A,Kerget B,SAGLAM L Analysis of one-year follow-up results and treatment costs of patients with PTE in a tertiary care center. Tüberküloz ve Toraks. 2023; 71(4): 390 - 399. 10.5578/tt.20239607 |
| Vancouver | Ergül E,Yilmazel Ucar E,Araz O,Aksakal A,Kerget B,SAGLAM L Analysis of one-year follow-up results and treatment costs of patients with PTE in a tertiary care center. Tüberküloz ve Toraks. 2023; 71(4): 390 - 399. 10.5578/tt.20239607 |
| IEEE | Ergül E,Yilmazel Ucar E,Araz O,Aksakal A,Kerget B,SAGLAM L "Analysis of one-year follow-up results and treatment costs of patients with PTE in a tertiary care center." Tüberküloz ve Toraks, 71, ss.390 - 399, 2023. 10.5578/tt.20239607 |
| ISNAD | Ergül, Ersin vd. "Analysis of one-year follow-up results and treatment costs of patients with PTE in a tertiary care center". Tüberküloz ve Toraks 71/4 (2023), 390-399. https://doi.org/10.5578/tt.20239607 |
